Mind Medicine Stock Price, News & Analysis

MindMed (Nasdaq: MNMD) has appointed Dr. Maurizio Fava to its Scientific Advisory Board. Dr. Fava, a leading psychiatrist from Massachusetts General Hospital and Harvard Medical School, brings extensive experience, having founded the hospital's Depression Clinical and Research Program and the Psychiatry Clinical Trials Network. With over $120 million in research funding and involvement in significant studies, his expertise is expected to enhance MindMed's development of psychedelic-inspired therapies. CEO Robert Barrow expressed enthusiasm for Dr. Fava's contributions to the company's mission.

MindMed (NASDAQ: MNMD) has appointed Dr. Peter Bergethon to its Scientific Advisory Board. Dr. Bergethon, Vice President at Biogen, brings expertise in neurology and digital medicine, aiming to enhance MindMed's efforts in developing psychedelic-inspired therapies for mental health and addiction. His background includes senior roles at Pfizer and academic positions at Boston and Tufts Universities. CEO Robert Barrow expressed confidence in Dr. Bergethon's ability to contribute to groundbreaking research and public health impacts as MindMed progresses in improving mental health treatment.

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announces the resignation of J.R. Rahn as CEO, effective immediately, with Robert Barrow taking over the role. Barrow, previously the company's Chief Development Officer, has extensive experience in pharmaceutical development and will lead the firm into later stage clinical trials. MindMed raised over US$204 million under Rahn, establishing itself as a leader in the psychedelic medicine sector. The transition aims to strengthen the company’s drug development initiatives and digital medicine strategies.

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced that all resolutions at the annual shareholder meeting held on May 27, 2021, were approved by requisite majorities. Notable outcomes include the re-election of six directors and the addition of Dr. Sarah Vinson, bringing the total to seven directors. Shareholders also approved the appointment of RSM Canada LLP as auditor and amendments to the Company's articles. Approximately 39.52% of shares were voted, highlighting strong shareholder engagement. CEO J.R. Rahn emphasized the importance of ongoing dialogue with shareholders.

MindMed (Nasdaq: MNMD), a psychedelic medicine biotech firm, has published the first pharmacogenetic data on LSD, which may help personalize dosing for patients. The study analyzed data from four Phase 1 trials conducted at the University Hospital Basel, revealing that genetic factors, especially CYP2D6 variations, significantly influence LSD metabolism and its psychological effects. The findings suggest that metabolic testing can inform individual LSD dosing. This research is a critical step in developing LSD as a medication, emphasizing the need for tailored patient treatment.

MindMed (NASDAQ: MNMD) has signed a Memorandum of Understanding (MOU) with Nextage Therapeutics (TASE: NXTG) to collaboratively develop a drug delivery system using Nextage's Brain Targeting Liposome System (BTLS) for ibogaine derivatives, including noribogaine. This partnership aims to optimize the efficacy of psychedelics while minimizing side effects, particularly for opioid addiction treatments. Both companies will share development costs and jointly own resulting intellectual property. If successful, this initiative could lead to significant advancements in psychedelic medicine.

MindMed (Nasdaq: MNMD) announced the approval of its first clinical trial evaluating mescaline's effects and its interaction with the serotonin 5-HT2A receptor. Conducted at the University Hospital Basel in Switzerland, the trial will begin this month. The study aims to provide modern scientific data on mescaline, which has historical significance yet lacks contemporary research. It will explore the dosing, subjective effects, and mechanisms of action of mescaline through a rigorous double-blind, placebo-controlled design. The results may lead to further investigations into mescaline's therapeutic potential.

On May 18, 2021, Mind Medicine (MindMed) (NASDAQ: MNMD) announced a partnership with The Chopra Foundation to enhance public awareness regarding psychedelic therapies for mental health. The collaboration aims to conduct research on psychedelic psychotherapy and its benefits for mental wellbeing, integrating digital therapeutics into treatment. The CEO, J.R. Rahn, emphasized the urgency for innovative mental health solutions, especially during Mental Health Awareness Month. This partnership may pave the way for new treatment modalities amidst a rising mental health crisis in the U.S.

MindMed has finalized its clinical development strategy for LSD, targeting Generalized Anxiety Disorder (GAD) as its initial indication. Following positive FDA feedback, the company plans to submit an Investigational New Drug (IND) application in Q3 2021, with a Phase 2b clinical trial expected to launch in Q4 2021. This trial will involve approximately 200 patients and aim to assess the efficacy of LSD in alleviating anxiety symptoms. The initiative marks a significant step in advancing psychedelic therapy for mental health issues, particularly since innovation in GAD treatment has lagged for decades.